Monsanto Company
https://www.monsanto.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Monsanto Company
Stock Watch: All Bayer’s Roads Lead To Unpalatable
Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.
Stock Watch: All Bayer’s Roads Lead To Unpalatable
Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.
Bayer To Settle Monsanto Litigation, Remains Prepared To Invest For Growth
The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.
Bayer To Settle Monsanto Litigation, Retains Capacity For Deals
The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice